Note 14 - Segment Information: Segment Information Table 1 (Details) (USD $)	3 Months Ended		9 Months Ended
	Jan. 31, 2014	Jan. 31, 2013	Jan. 31, 2014	Jan. 31, 2013
Details
Revenue Chinese medicine - third party	$ 713,896	$ 1,111,530	$ 1,862,718	$ 2,475,830
Revenue Chinese medicine - related party	0	0	0	0
Revenue Chinese medicine	713,896	1,111,530	1,862,718	2,475,830
Revenue Stevioside - third party	1,680,795	687,414	4,338,845	3,615,509
Revenue Stevioside - related party	833,657	171,547	2,567,648	1,576,463
Revenue Stevioside	2,514,452	858,961	6,906,493	5,191,972
Total segment and consolidated revenues	3,228,348	1,970,491	8,769,211	7,667,802
Interest income (expense) Chinese medicine	92	1,667	370	1,733
Interest income (expense) Stevioside	(35,573)	(1,030)	(69,101)	4,719
Interest income (expense) Corporate and other	0	0	0	1,718
Total segment and consolidated interest income (expense)	(35,481)	637	(68,731)	8,170
Depreciation and amortization Chinese medicine	31,963	19,811	77,996	59,197
Depreciation and amortization Stevioside	432,169	532,909	1,311,822	1,358,451
Depreciation and amortization Corporate and other	81,294	0	243,881	0
Total segment and consolidated depreciation and amortization	$ 545,426	$ 552,720	$ 1,633,699	$ 1,417,648